Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357288 | 0.95 | MEN1 (0.54) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10887373 | 0.93 | MEN1 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| Acetic Acid SCHEMBL5682952 | 0.86 | MEN1 (0.47) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| SCHEMBL28524487 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL28526307 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL28524486 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL29855657 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL8164565 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL13331169 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL21207110 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| EP-3183248-B1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-107108581-B | Tieback benzamide derivatives as potent ROCK inhibitors | 百时美施贵宝公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-107108581-A | Tieback benzamide derivatives as potent ROCK inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016028971-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016020295-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2016-02-11 | — | — | WO | disclosed |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | MYLK, ROCK1, MYLK2 | CHRNB2 1674/4885CHRNA7 2486/4885CHRNA4 2858/4885 |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | CHRNB2 1956/4885CHRNA7 2225/4885CHRNA4 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.